S&P 500   5,011.12
DOW   37,775.38
QQQ   422.83
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   422.83
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   422.83
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook
S&P 500   5,011.12
DOW   37,775.38
QQQ   422.83
How major US stock indexes fared Thursday, 4/18/2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
Shares of Walmart-backed Ibotta soar on public debut
Closing prices for crude oil, gold and other commodities
IMF's Georgieva says there's 'plenty to worry about' despite recovery for many economies
World Bank's Banga wants to make gains in tackling the effects of climate change, poverty and war
Taiwan Semiconductor Earnings: AI Dominance and Future Outlook

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$6.74
-1.2%
$4.75
$1.86
$9.01
$17.46M1.0364,015 shs13,836 shs
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
-4.5%
$0.13
$0.07
$1.95
$2.89M1.973.42 million shs99,850 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
-4.5%
$0.13
$0.07
$1.95
$2.89M1.973.42 million shs99,850 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$0.64
-1.6%
$0.79
$0.50
$6.85
$2.92M1.44131,301 shs61,688 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
+42.08%+9.47%+34.52%+139.30%+74.42%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-53.85%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+3.45%-6.25%-39.17%-44.95%+8,399,900.00%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+3.45%-6.25%-39.17%-44.95%+8,399,900.00%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-1.01%-9.22%-35.40%-5.93%-84.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
1.4723 of 5 stars
3.53.00.00.02.30.80.0
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.4064 of 5 stars
3.55.00.00.00.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
3.00
Buy$10.0048.37% Upside
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.00
Buy$4.00529.92% Upside

Current Analyst Ratings

Latest PHIO, BNTC, MSLP, NBY, and NBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/15/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
2/6/2024
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
1/24/2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
$80K218.21N/AN/A$0.12 per share56.17
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.20N/AN/A$0.12 per share0.67
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.20N/AN/A$0.12 per share0.67
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$2.06 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
-$19.56MN/A0.00N/AN/A-204.34%-142.81%5/20/2024 (Estimated)
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.15N/A-65.46%-150.14%-53.48%N/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.15N/A-65.46%-150.14%-53.48%N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$10.83M-$5.93N/AN/AN/A-134.66%-105.86%5/9/2024 (Estimated)

Latest PHIO, BNTC, MSLP, NBY, and NBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    
2/13/2024Q2 2024
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/A-$2.64-$2.64-$2.64N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
0.01
3.62
3.62
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
5.70
5.71

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
52.19%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Benitec Biopharma Inc. stock logo
BNTC
Benitec Biopharma
182.59 million2.48 millionNo Data
MusclePharm Co. stock logo
MSLP
MusclePharm
2733.39 million13.12 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
94.59 million4.56 millionNot Optionable

PHIO, BNTC, MSLP, NBY, and NBY Headlines

SourceHeadline
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
globenewswire.com - April 16 at 7:30 AM
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
globenewswire.com - April 11 at 7:30 AM
National Spotlight Features Phio’s Innovative RNAi Technology PlatformNational Spotlight Features Phio’s Innovative RNAi Technology Platform
finance.yahoo.com - April 3 at 10:33 AM
National Spotlight Features Phios Innovative RNAi Technology PlatformNational Spotlight Features Phio's Innovative RNAi Technology Platform
globenewswire.com - April 3 at 7:30 AM
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdatePhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
globenewswire.com - April 2 at 7:30 AM
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
finance.yahoo.com - March 21 at 7:52 AM
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
globenewswire.com - March 13 at 2:00 PM
Phio Pharmaceuticals Corp PHIOPhio Pharmaceuticals Corp PHIO
morningstar.com - March 10 at 7:10 AM
Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)
markets.businessinsider.com - March 6 at 6:26 PM
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
finance.yahoo.com - March 6 at 6:26 PM
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Companys Intellectual Property Position in Treating Aging Skin and Skin DisordersPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
globenewswire.com - March 6 at 10:30 AM
Challenges and Opportunities for Key Players in the Hypopigmentation Disorder Product MarketChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Market
opprairie.com - February 23 at 1:35 PM
Dry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030Dry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030
uk.finance.yahoo.com - February 14 at 10:33 AM
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)
markets.businessinsider.com - February 6 at 1:30 PM
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
finance.yahoo.com - January 31 at 8:14 AM
Phio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of ListingPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listing
cbonds.com - January 28 at 12:19 PM
Recent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)Recent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)
knoxdaily.com - January 1 at 1:39 PM
Phio Pharmaceuticals files to sell 4.42M shares of common stock for holdersPhio Pharmaceuticals files to sell 4.42M shares of common stock for holders
msn.com - December 19 at 9:00 PM
Why Phio Pharmaceuticals Stock Is NosedivingWhy Phio Pharmaceuticals Stock Is Nosediving
msn.com - December 7 at 5:55 PM
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
finance.yahoo.com - December 7 at 12:54 PM
Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - November 10 at 1:31 PM
Phio Pharmaceuticals enrolls first patient in clinical trialPhio Pharmaceuticals enrolls first patient in clinical trial
wbjournal.com - November 10 at 1:31 PM
Phio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29Phio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29
msn.com - November 10 at 1:31 PM
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatePhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 8:25 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma logo

Benitec Biopharma

NASDAQ:BNTC
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
MusclePharm logo

MusclePharm

OTCMKTS:MSLP
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Phio Pharmaceuticals logo

Phio Pharmaceuticals

NASDAQ:PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.